Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50872 |
Name | large cell neuroendocrine carcinoma |
Definition | A lung large cell carcinoma that derives_from neuroendocrine cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung large cell carcinoma large cell neuroendocrine carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
EML4 - ALK | Alectinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180L ALK G1202R | Alectinib | large cell neuroendocrine carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK V1180L ALK G1202R | Brigatinib | large cell neuroendocrine carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK V1180L ALK G1202R | Lorlatinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180L | Alectinib | large cell neuroendocrine carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196M | Brigatinib | large cell neuroendocrine carcinoma | no benefit | detail... |
EML4 - ALK ALK L1196M ALK G1202R ALK D1203N | Lorlatinib | large cell neuroendocrine carcinoma | predicted - resistant | detail... |
ALK rearrange | Alectinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Alectinib + Zoledronic acid | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
BRAF G469R | Dabrafenib + Trametinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Brigatinib | large cell neuroendocrine carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
NCT04079712 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | Active, not recruiting | USA | CAN | 0 |
NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
NCT04429087 | Phase I | BI 764532 | A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Recruiting | USA | ESP | DEU | 1 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |
NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
NCT05882058 | Phase II | BI 764532 | DAREO-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT06132113 | Phase I | BI 764532 + Cisplatin + Etoposide BI 764532 + Carboplatin + Etoposide | DAREON-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Recruiting | USA | SWE | NLD | FRA | ESP | DEU | BEL | 1 |
NCT06176989 | Phase II | Enasidenib | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Recruiting | USA | 0 |
NCT06418087 | Phase II | Carboplatin + Durvalumab + Etoposide | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE) | Recruiting | ITA | 0 |